Osiris Therapeutics Board Confirms Lode Debrabandere As CEO

(RTTNews) - Osiris Therapeutics, Inc. (OSIR) said Tuesday that its Board of Directors has confirmed the nomination of Lode Debrabandere as President and Chief Executive Officer.

In addition to President and CEO, Dr. Debrabandere was elected to the company's Board of Directors. He will fulfill the remaining term of C. Randal Mills as a Class II Director and will stand for re-election by the company's Stockholders at its 2014 Annual Meeting.

Dr. Debrabandere joined Osiris in 2006 as Vice President and General Manager of the Therapeutics Business Unit and was responsible for the development of Prochyma, the world's first approved stem cell drug for graft versus host disease. In 2012, he was promoted to Chief Operating Officer and assumed responsibility for all commercial activities of the company.

Prior to joining Osiris, Dr. Debrabandere served as Vice President of Global Marketing at Bristol Myers Squibb (BMY) where he led the Neuroscience Business Unit and was the Global Brand Leader for Abilify.